Chikungunya Vaccine Trial Begins to Enroll Participants
NIH Scientists Developed Experimental Vaccine
An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health. The vaccine was developed by researchers at the NIAID Vaccine Research Center (VRC) using non-infectious virus-like particles to prompt an immune response. The trial is testing the vaccine’s safety and ability to elicit antibodies against chikungunya virus. It will enroll 25 healthy adults aged 18 to 50 years.
Learn more at: http://www.niaid.nih.gov/news/newsreleases/2011/Pages/ChikungunyaVaxTrial.aspx
Chikungunya Vaccine Trial Begins Enrollment